# GSTM1 new study: cisplatin kidney injury in context

> A 2026 paper links GSTM1 loss to worse cisplatin kidney injury; BioQ shows what DepMap, Open Targets, ChEMBL, Reactome and STRING say about GSTM1 today.

Data as of 2026-11-16 · Published 2026-11-16 · Updated 2026-11-16 · https://bioq.bio/blog/en/gstm1-gstm1-deficiency-exacerbates-cisplatin-induced-kidney-injury-via-inc

![BioQ result page for the query GSTM1 showing dependency, disease association, pathway and interaction panels, each labelled with its source.](https://bioq.bio/blog/img/gstm1-gstm1-deficiency-exacerbates-cisplatin-induced-kidney-injury-via-inc/en/hero.webp)

A 2026 paper in Clinical Science reports that GSTM1 deficiency worsens cisplatin-induced kidney injury through oxidative stress. BioQ's public data, as of 2026-11-16, add context from a different angle. GSTM1 is not a common essential gene in DepMap: 2 of 1059 cell lines depend on it (0.2%). It sits in 7 Reactome pathways and has 891 STRING partners.

## What we asked: where this GSTM1 new study fits

The paper asks whether losing a phase II detoxification enzyme changes how badly the kidney is hurt by cisplatin. It works in mouse models and in cultured kidney cells. Its results, and its interpretation of them, belong to the paper. BioQ did not test any of them and does not reproduce them here.

Our question is narrower. If you meet this paper and want to place GSTM1 in one minute, what do the public data layers say about the gene today? We asked about:

- how much cancer cell lines depend on it
- which pathways it belongs to
- which proteins it is linked to
- which diseases and drugs are attached to it
- how its expression differs between tumour and normal tissue

## What BioQ returned

One query, GSTM1, drew on 6 distinct resources. It ran 7 engine queries in 2.1 engine seconds in total. The sections below cover what each layer returned.

### Dependency: GSTM1 is not a typical vulnerability

DepMap reports a mean Chronos gene effect of 0.068 across 1059 cell lines, and the gene is not flagged as common essential. A more negative Chronos value means the knockout reduced viability more, so a value near zero or above means that knocking GSTM1 out did little to growth in these culture models. The 2 dependent lines are counted against a named threshold, which is a convention and not a property of the data. The top of the lineage table is shown below.

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Breast | 48 | 1 | 2.1 | 0.027 |
| Peripheral Nervous System | 35 | 0 | 0 | 0.038 |
| CNS/Brain | 78 | 0 | 0 | 0.044 |
| Skin | 73 | 0 | 0 | 0.046 |
| Bone | 38 | 0 | 0 | 0.049 |
| Thyroid | 11 | 0 | 0 | 0.051 |
| Pancreas | 39 | 0 | 0 | 0.054 |
| Prostate | 8 | 0 | 0 | 0.055 |

![BioQ DepMap panel for GSTM1 showing CRISPR dependency by lineage with Chronos gene effect](https://bioq.bio/blog/img/gstm1-gstm1-deficiency-exacerbates-cisplatin-induced-kidney-injury-via-inc/en/dep.webp)
*DepMap Chronos gene effect for GSTM1 by lineage, as returned by BioQ.*

Breast has the only dependent line among the lineages listed (1 of 48). Every other lineage in the table has 0 dependent lines.

### Pathways: where the enzyme sits

Reactome places GSTM1 in 7 pathways. The five most specific are below.

| Pathway | Reactome ID | Genes in pathway |
|---|---|---|
| Azathioprine ADME | R-HSA-9748787 | 23 |
| Paracetamol ADME | R-HSA-9753281 | 30 |
| Glutathione conjugation | R-HSA-156590 | 37 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 106 |
| Drug ADME | R-HSA-9748784 | 110 |

Glutathione conjugation (R-HSA-156590, 37 genes) is the closest match to the paper's theme of detoxification and oxidative stress. The same gene also appears in drug-metabolism pathways such as Paracetamol ADME and Azathioprine ADME.

### Interaction partners

STRING v12 lists 891 partners. The top six are shown below.

| Partner | UniProt | STRING combined score |
|---|---|---|
| GSTM2 | P28161 | 999 |
| CYP1A1 | P04798 | 991 |
| EPHX1 | P07099 | 985 |
| SPP1 | P10451 | 981 |
| CYP2E1 | P05181 | 976 |
| CYP1B1 | Q16678 | 962 |

The top partner is the paralog GSTM2 (score 999). Several of the others are xenobiotic-metabolising enzymes: CYP1A1, EPHX1, CYP2E1 and CYP1B1. STRING scores combine several kinds of evidence, including text mining and co-expression, so a high score does not mean a direct physical interaction.

### Diseases, drugs and tumour expression

Open Targets lists 2053 diseases associated with GSTM1. The six top-scoring ones are lipid and fatty-acid measurements, led by high density lipoprotein cholesterol measurement (score 0.548, 50 evidence items). The scores in the six shown run from 0.548 down to 0.474. These associations come mostly from genetic-association style evidence on blood traits. They are not about kidney injury or cisplatin.

For drugs, BioQ returns 1 entry: Glutathione, at approval stage, with 22 trials found by name. It has no exact pChEMBL value recorded, so there is no ChEMBL exact IC50 to report for GSTM1 here. The data show no selective GSTM1 inhibitor with measured potency.

TCGA and GTEx data cover 24 cancer types that have both tumour and normal samples. In several of them, mean GSTM1 expression is lower in tumour than in normal tissue:

- Prostate adenocarcinoma: 6.23 in 495 tumours against 8.95 in 52 normals (log2 fold -0.52).
- Colon adenocarcinoma: 5.82 against 8.12.
- Thymoma: 6.28 against 11.71, but only 2 normal samples.
- Sarcoma: the opposite direction, 6.13 in 258 tumours against 3.21 in 2 normals (log2 fold 0.93).

## What it means and how to read it

The data are a backdrop for the paper and do not test its claim. Three readings are reasonable.

1. **Low dependency fits a detoxification role.** A gene that most cancer lines can lose without a growth penalty is consistent with a protective, context-dependent enzyme and not a core survival gene. This is a consistency check, not evidence for the paper's mechanism.
2. **The pathway and partner context points the same way as the paper's theme.** Glutathione conjugation, Phase II conjugation and a set of xenobiotic-metabolising partners all place GSTM1 in the detoxification network. The paper's own data would have to show whether that network explains the kidney findings.
3. **Open Targets does not yet carry the paper's question.** The top disease terms are lipid traits, and the drug layer holds no GSTM1-selective compound with a measured potency. Anyone wanting to modulate GSTM1 pharmacologically will find little to start from in these public layers.

## How to reproduce it in BioQ

1. Open BioQ and enter the gene symbol as the whole query.
2. Run it. BioQ sends the query to the dependency, pathway, interaction, disease, drug and expression layers together.
3. Open each panel and check the release and source label shown with it.

```text
GSTM1
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DGSTM1)

4. Compare the DepMap Chronos gene effect panel with the Reactome and STRING panels.
5. Export the tables if you want to keep a dated record. These numbers are as of 2026-11-16 and will change with new data releases.

Done by hand, this would mean visiting each of the 6 resources separately and matching gene identifiers between them. BioQ ran the 7 engine queries in 2.1 seconds. That figure is engine time only and does not include your reading time.

## Limits: what the data do not show

- **No kidney data.** None of the layers above describe renal tissue, proximal tubule cells or cisplatin exposure. The paper's kidney findings cannot be confirmed or refuted from this page.
- **Cancer cell lines are not kidney.** DepMap measures viability after CRISPR knockout in cancer lines. It says nothing about oxidative stress responses in healthy kidney cells.
- **Gene variants are not resolved.** The paper concerns a deficiency of GSTM1. These panels treat GSTM1 as one gene and do not report which cell lines or tumours carry a deletion.
- **Small normal groups.** Several TCGA/GTEx comparisons rest on only 1 to 3 normal samples, so the fold changes for thymoma, cervical cancer, melanoma and sarcoma are weak evidence.
- **Association is not mechanism.** STRING scores and Open Targets scores show that evidence exists, not what it means biologically.
- **No clinical guidance.** Nothing here informs treatment choices or dosing.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-16 (7 queries, 2.1 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/depmap`, `/drugs`, `/interaction`, `/ot_association`, `/pathway`, `/tcga`

## Sources
- GSTM1 Deficiency Exacerbates Cisplatin-Induced Kidney Injury via Increased Oxidative Stress (2026) — [doi:10.1042/cs20250134](https://doi.org/10.1042/cs20250134)

Run the same query yourself: [GSTM1](https://bioq.bio/login?next=%2Fapp%23q%3DGSTM1)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`GSTM1`](https://bioq.bio/login?next=%2Fapp%23q%3DGSTM1)

## Frequently asked questions

### Is GSTM1 an essential gene in DepMap?

No. In depmap_24q4, 2 of 1059 cell lines depend on GSTM1 (0.2%), the mean Chronos gene effect is 0.068, and the gene is not flagged as common essential.

### Which pathways is GSTM1 part of in Reactome?

Reactome lists 7 pathways for GSTM1. They include Glutathione conjugation (R-HSA-156590, 37 genes), Phase II - Conjugation of compounds (R-HSA-156580, 106 genes) and Drug ADME (R-HSA-9748784, 110 genes).

### Are there GSTM1 inhibitors with measured potency in ChEMBL?

Not in this result. BioQ returns 1 drug, Glutathione, at approval stage with 22 trials found by name, and it has no exact pChEMBL value recorded.

### What are GSTM1's top interaction partners in STRING?

STRING v12 lists 891 partners for GSTM1. The top one is GSTM2 with a combined score of 999, followed by CYP1A1 (991) and EPHX1 (985).

### Does Open Targets link GSTM1 to kidney disease?

Open Targets lists 2053 diseases for GSTM1, but the six top-scoring ones shown are lipid and fatty-acid measurements, led by high density lipoprotein cholesterol measurement at 0.548. Kidney injury is not among those six.

## Sources

- Paper: [GSTM1 Deficiency Exacerbates Cisplatin-Induced Kidney Injury via Increased Oxidative Stress](https://doi.org/10.1042/cs20250134) (2026) DOI 10.1042/cs20250134
- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)
- Dataset: [TCGA pan-cancer expression (UCSC Xena Toil recompute)](https://xenabrowser.net/)
- Dataset: [Reactome pathway knowledgebase](https://reactome.org/)
- Dataset: [STRING v12 protein-protein interactions](https://string-db.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
